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to ﬁrst line therapy with tacrolimus/steroids is high. How-
ever, a substantial number of patients required salvage treat-
ment and mortality continues to be high. Earlier intervention
for the prevention of both acute and chronic forms of GvHD is
warranted.
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PENTOSTATIN AND CYCLOSPORINE, A NEW REGIMEN FOR THE
PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER
ALLOGENEIC PERIPHERAL BLOOD PROGENITOR CELL TRANSPLAN-
TATION
Schwartz, J.E., Carroll, M.P., BuchBarker, D.M., Grifﬁn, D.L.,
Schwartz, R.N., Tompkins, C.A., Donnenberg, A.D., Agha, M.E.,
Evans, C., Burgunder, M.R., Yeager, A.M. University of Pittsburgh
Cancer Institute, Pittsburgh, PA.
Acute graft-versus-host disease (AGVHD) is a major cause of
morbidity and mortality after allogeneic hematopoietic cell
transplantation. Common preventive strategies include cyclo-
sporine (CSP) or tacrolimus plus short-course iv methotrexate
(MTX). Pentostatin (PEN), a purine nucleoside analog, has
been used to treat steroid-refractory acute and chronic GVHD
but not to prevent AGVHD. We conducted a phase II study to
evaluate the efﬁcacy of short-course PEN plus CSP for GVHD
prophylaxis in 10 patients (pts) (6 M, 4 F; median age 34 yr;
range 18-49 yr) with AML(1), ALL(2), CML(2), NHL(3)
MM(2) who were undergoing allogeneic PBPCT from HLA-
identical sibs. Preparative regimens were: busulfan (BU) and
cyclophosphamide(CY) (5); total body irradiation(TBI) and CY
(2); BU, CY and etoposide (2); or TBI and melphalan (1). All pts
received CSP, initially by continuous iv infusion, beginning at
day (d) –2. PEN was administered i.v. at a dose of 1.0 mg/m2 on
d1 and at a dose of 0.5 mg/m2 on d3, 6 and 11. Pts
received a median of 9.24 (range, 5.38–13.9) x 106 CD34
cells/kg and a median of 3.52 (range 2.03–6.02) x 108 CD3
cells/kg. Median time to absolute lymphocyte count (ALC) 0.2
x 109/L was 9d (range, 0-13 d) after PBPCT and to absolute
neutrophil count (ANC) 0.5 x 109/L was 10d (range, 8-15 d).
In 9 pts, the median time to attain platelets 20 x 109/L was 16d
(range, 10-27 d); 1 pt never had platelet recovery. Grades of
AGVHD were: 0 (2), I (1), II (3), III (3) and IV (1). The
incidence of Grade II-IV AGVHD was 70% and of Grade
III-IV AGVHD was 40%. AGVHD responded to steroids in 3
pts but was steroid-refractory in 4 pts, requiring mycophenolate
mofetil (MMF; 2 pts) or MMF plus anti-thymocyte globulin (2
pts). Two pts died from GVHD-related complications at d108
and d112 after PBPCT. All 8 evaluable pts developed chronic
GVHD (CGVHD; 2 limited, 6 extensive); extensive CGVHD
developed in 3 pts after intentional withdrawal of immunosup-
pression and in 1 pt because of non-compliance with CSP.
Three pts (1 AML, 1 ALL, 1 MM) relapsed at d180, 188 and
266, respectively; 2 attained remissions after immunosuppres-
sion withdrawal. Eight pts are alive at a median of 443 d
(range, 181–721 days) after PBPCT (overall survival, 80%).
We conclude that PEN may be an alternative to MTX for
AGVHD prophylaxis. The observed incidence of Grade II-IV
AGVHD and of CGVHD suggests that higher doses and/or
longer duration of PEN may be needed to improve efﬁcacy of
this regimen.
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COMPARISON OF LYMPHOID AND MYELOID ENGRAFTMENT RATES IN
PATIENTS RECEIVING FLUDARABINE/TBI OR FLUDARABINE/CYCLO-
PHOSPHAMIDE FOR NON-MYELOABLATIVE ALLOGENEIC TRANSPLAN-
TATION
Mellon-Reppen, S., Dansey, R., Abella, E., Nehlsen-Cannarella, S.,
Abidi, M.H. Karmanos Cancer Institute, Detroit, MI; Wayne State
University, Detroit, MI.
Non-myeloablative allogeneic transplants are used in place of
ablative transplants in selected patients with poor performance
status or abnormal vital organ function. They have been per-
formed in patients with low grade NHL, Hodgkin’s disease,
multiple myeloma and renal cell carcinoma. The conditioning
regimen is an important element of the procedure as it contrib-
utes to the speed and rate of donor lymphoid and myeloid
engraftment.
We report engraftment and GVHD rates of ﬂudarabine/TBI
(FluTBI) compared to ﬂudarabine/cyclophosphamide (FluCy).
From 09/2000 to the present, ﬂudarabine 30mg/m2 x 3 days
with TBI 200cGy was given to 12 patients and ﬂudarabine
25mg/m2 x 5 days with cyclophosphamide 60mg/m2 x 2 days was
given to 28 patients. Post-transplant immunosuppression was
identical for both regimens with mycophenolate and cyclo-
sporine. Diagnoses included renal cancer 13, myeloma 7, NHL
6, AML/MDS 4, breast cancer 3, Hodgkin’s disease 3, CLL 2,
CML 1 and pancreatic cancer 1. Twenty three donors were
siblings and 17 were unrelated volunteers. Lymphoid and
myeloid engraftment were evaluated by peripheral blood STR
and expressed as percent donor cells. Results are reported as
median values. By ANOVA testing there are signiﬁcant differ-
ences between conditioning regimens for lymphoid engraftment
at day 14 (p  0.027) and day 28 (p  0.024). The range of
percent donor lymphoid cells was similar for both regimens at
all time points. Two (17%) patients who received FluTBI re-
jected the graft. One patient was reconditioned successfully with
FluCy. No patients receiving FluCy rejected. Acute graft versus
host disease occurred in 66% of patients conditioned with
FluCy compared to 58% (p  NS) receiving FluTBI and
chronic graft versus host disease occurred in 45% of FluCy
patients versus 50% (p  NS) of FluTBI patients. Twelve (29%)
patients have achieved CR with no difference (28% FluCy vs
33% FluTBI) between conditioning regimens.
FluCy is associated with signiﬁcantly more rapid donor lymphoid
engraftment and this is potentially important when attempting to
balance regimen morbidity with need for engraftment due to
disease progression.
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ABSENCE OF INDUCIBLE COSTIMULATOR ON ALLOREACTIVE T CELLS
REDUCES GRAFT-VERSUS-HOST-DISEASE WHILE LEAVING GRAFT-VER-
SUS-TUMOR ACTIVITY INTACT
Tjoe, K.H., Eng, J.M., Alpdogan, O., Muriglan, S.J., Hubbard, V.M.,
Kochman, A.A., Schiro, R., van den Brink, M.R.M. Memorial Sloan-
Kettering Cancer Center, New York, NY.
Inducible costimulator (ICOS) has been recognized as a costimu-
latory molecule essential in T cell activation. Studies with ICOS
inhibition or ICOS
/
 recipients have demonstrated prolonged
allograft survival after heart or liver transplantation in animal
models. We hypothesized that inhibition of ICOS on alloreactive
Table. Engraftment Data Related to Conditioning Regime
Day Post-BMT 14 30 60 90 180 360
% Donor lymphoid FluCy 95 95 95 100 100 100
% Donor lymphoid FluTBI 63 78 87 75 100 100
% Donor myeloid FluCy 95 94 95 100 100 100
% Donor myeloid FluTBI 55 100 99 100 100 100
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T cells would ameliorate the development of graft-versus-host-
disease (GVHD) in recipients of an allogeneic bone marrow trans-
plantation (allo-BMT). To analyze the expression of ICOS on
donor T cells, we transferred CFSE-labeled donor T cells into
irradiated allogeneic recipients and observed an increased expres-
sion of ICOS on alloreactive T cells compared to non-alloreactive
T cells. We then performed GVHD experiments in two models
with full MHC class I and II disparity and observed signiﬁcantly
less GVHD morbidity and mortality in recipients of ICOS
/

donor T cells. Interestingly, in GVHD/graft-versus-tumor (GVT)
experiments, ICOS
/
 donor T cells displayed intact GVT ac-
tivity, while their GVH activity was diminished. We are currently
performing experiments to assess the alloreactivity of ICOS
/
 T
cells in vivo, the inﬁltration of ICOS
/
 donor T cells into
GVHD target organs, and the degree of GVHD damage in target
organs by histopathological analysis. In conclusion, we have found
that ICOS
/
 donor T cells cause less GVHD morbidity and
mortality in comparison to wild-type donor T cells while preserv-
ing GVT activity. This data suggests that strategies to inhibit
ICOS could be useful for the prevention and/or treatment of
GVHD in recipients of an allo-BMT.
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ADOPTIVE TRANSFER OF PRIMED T CELLS PRIOR TO ABLATIVE CON-
DITIONING AND BMT RESULTS IN SYNGENEIC ANTI-TUMOR IMMU-
NITY EARLY POST-TRANSPLANT
Jones, M., Jones, A.M., Levy, R.B. University of Miami School of
Medice, Miami, FL.
We have shown that mice vaccinated against a B6 myeloid leu-
kemia cell line (MMB3.19) prior to BMT followed by tumor
challenge post-BMT exhibited tumor speciﬁc immunity. Vacci-
nated BMT recipients exhibited prolonged survival compared to
unvaccinated BMT recipients indicating that anti-tumor reactive T
cells survived the conditioning regimen and subsequent autologous
BMT. To investigate T cell survival and function early after abla-
tive conditioning and BMT, an adoptive transfer BMT model
(AT-BMT) was developed. Since memory cells appear less suscep-
tible to irradiation induced apoptosis vs. naive cells, B6-gfp mice
were immunized with irradiated MMB3.19 cells 5-6 weeks before
the BMT as a source of anti-tumor primed T cells for adoptive
transfer (AT). Two days prior to BMT, 2.5x107 CD3 cells from
vaccinated donor B6-gfp mice were injected (i.p.) into naive
C57BL/6 (B6-gfp-) recipients. One day later (D-1), recipient mice
were conditioned with 8.5Gy TBI and at D 0 were injected with
TCD syngeneic B6-gfp- marrow. On D1 post-BMT, mice re-
ceived an ip challenge of 2.5x104 viable MMB3.19 cells. AT-BMT
recipients exhibited signiﬁcantly increased MST vs. non-ATBMT
controls (control: MST  13.8 days vs. AT-BMT: MST  40
days). To examine if so-called “low quality” CD8 T cells could
protect in this model, B6-wt and B6-CD4
/
 mice were primed 6
weeks prior to AT. Recipients received an AT of 2.5x107 CD4
and CD8 B6-wt (CD8  1.2x107) or CD4-CD8(1.2x107 cells)
on D-2 and were irradiated, transplanted and challenged with
tumor as above. In contrast to B6-wt T cells, recipients of CD4-
CD8T cells were not protected from tumor challenge. Following
transplant, spleen and peritoneal exudate cells (PEC) were ana-
lyzed for the presence of surviving AT cells. Transferred B6-gfp
cells were readily detected at Days4 and11 in the spleen (0.5%
and 1.5%, respectively) of AT-BMT recipients injected with tumor
post-BMT. Notably, a large percentage of gfp cells were identi-
ﬁed in the PEC of these AT-BMT mice at these time points
(10.7% and 50.9%, respectively). In total, these results demon-
strate that memory T cells can survive ablative BMT conditioning
and contribute to an effective immune response (i.e., anti-tumor) in
the early post-transplant period during lymphohematopoietic re-
constitution. These observations suggest that approaches to in-
crease selective host T cell survival during BMT may be useful to
diminish immune deﬁciency in the immediate post-transplant pe-
riod.
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UNRELATED DONOR STEM CELL TRANSPLANTATION DOES NOT RE-
SULT IN LONG TERM REMISSION IN PATIENTS WITH MULTIPLE MY-
ELOMA DESPITE THE PRESENCE OF CHRONIC GVHD
Reynolds, C.M., Ratanatharathorn, V., Ayash, L.J., Silver, S.M., Daw-
son, L.A., Ferrara, J.L.M., Uberti, J.P. Univ of Michigan Stem Cell
Transplantation Program, Ann Arbor, MI.
Autologous SCT increases survival for patients with multiple
myeloma compared to conventional chemotherapy but is not con-
sidered curative as most patients eventually relapse. Allogeneic
SCT improves the CR rate and can result in a graft versus myeloma
(GVM) effect, but not all patients have a related donor. We
performed unrelated SCT using either a full or reduced intensity
preparative regimen. Patients with stage II or III multiple myeloma
who had relapsed following at least one prior therapy were eligible.
From January 1996 to May 2001 thirteen patients were enrolled.
Prior to SCT, patients had received a median number of 3 prior
regimens (range, 1-5). Six patients had previously received radia-
tion, and three had previously undergone an autologous transplant.
The median age at transplant was 50 years (range 38-62). Six
patients received a full intensity preparative regimen of total body
irradiation (TBI), busulfan, and cyclophosphamide, and seven pa-
tients received a reduced intensity regimen of total lymphoid irra-
diation, ﬂudarabine, and busulfan. All patients received HLA-
matched, unrelated donor BM (n  7) or peripheral stem cell (n 
6) transplants. The median mononuclear cell dose was 3.4 x 108 per
kg (range, 1.2–7.0). GVHD prophylaxis consisted of tacrolimus
and methotrexate. Three patients developed grade 3 aGVHD and
six developed cGVHD (1 limited, 5 extensive). The median fol-
lowup for all patients was 26.6 months (range 0.5–77.8). At the
time of SCT, nine patients had chemosensitive disease and two
patients were in CR. After transplant, six patients were in CR, ﬁve
had a PR and one had a stable monoclonal restriction. Seven
patients developed progressive disease at a median of 20.8 months
(range 3.2–39.8) post-transplant, four in the setting of extensive
cGVHD. Ten patients died (5 from relapse, 3 GVHD, 1 VOD,
and 1 pneumonia/ARDS). Three patients are alive with stable,
asymptomatic monoclonal restrictions at 26.6, 36.8, and 77.8
months after SCT. The Kaplan-Meier estimates at 1, 3 and 5 years
for overall survival were 54%, 26%, and 13 %, and for progression-
free survival were 54%, 15% and 7%, respectively. In this popu-
lation of heavily pretreated patients, unrelated donor transplanta-
tion did not result in long-term disease control despite the
presence of cGVHD and suggests that the GVM effect was not
sufﬁcient to prevent relapse.
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UNRESTRICTED CTL RECOGNITION OF HFE, AN EMPTY-PEPTIDE–
GROOVE MHC CLASS I MOLECULE CONTROLLING IRON METABOLISM
HIGHLIGHTS ITS POTENTIAL ROLE AS A MAJOR HISTOCOMPATIBILITY
ANTIGEN IN UNRELATED BONE MARROW TRANPLANTATION
Rohrlich, P.S.1, Firat, H.1, Fazilleau, N.1, Ehrlich, R.2, Gluckman, E.3,
Loiseau, P.3, Lemonnier, F.1 1. Institut Pasteur, Paris, France; 2.
University, Tel-Aviv, Israel; 3. Hopital Saint Louis, Paris, France.
Unrestricted cytolytic T lymphocytes (CTL) responses against
human HFE, a non classical MHC class I molecule with an empty
peptide groove which controls iron metabolism, were induced in
HLA-A*0201 transgenic/H-2 class I knock-out mice. HFE recog-
nition was mediated by the alpha-beta T cell receptor. Similar
unrestricted CTL responses against mouse HFE molecule were
induced in DBA/2 HFE knock-out mice. Predominant usage of AV
6 segments was documented, contrasting with diversiﬁed V
segment usage. Thus absence of bound ligand to a histocompati-
bility class I molecule does not preclude  TCR interaction.
These results support the hypothesis that the immune system could
participate in the control of iron metabolism and indicate a novel
unrestricted allogenic recognition mechanism that could explain
the high proportion of allogenic cytotoxic precursors encountered
in any individual.
Ten to 15% of the individuals carry a mutated H41D HFE
molecule. Since HFE is encoded on the chromosome 6 and thus
cosegregates with the HLA haplotypes in siblings, a HFE mis-
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